Delivery Order SPE2DB22D2108-SPE2DB25FU5JF
- Not listed
- The Defense Logistics Agency awarded a $2,558.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injectors. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999.99 billion ceiling value through December 2026. The delivery order is non-set-aside and was competitively awarded. Performance will be...
- The Defense Logistics Agency (DLA) awarded a $1,629.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector pharmaceutical supplies, with an ultimate completion date of July 21, 2025. This non-set-aside competitively awarded contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a $2,150.75 delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,646.02 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitive award under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a...
- The Defense Logistics Agency awarded a delivery order valued at $1,293.84 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the same municipality....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector pharmaceutical products, valued at $3,572.94 under a firm fixed-price delivery order contract. The award, issued on July 31, 2025, with completion scheduled for August 1, 2025, represents a non-competitive delivery order without set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,358.05 to AmerisourceBergen Drug Corp for XYOSTED 50 MG/0.5 ML auto-injectors (0.5 ML) on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order was not set-aside and competitively awarded. The product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's broader...
- This delivery order, awarded July 28, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides Xyosted 100 mg/0.5 mL auto-injector pharmaceutical supplies with a ceiling value of $1,092.55. The contract utilizes firm fixed pricing and is scheduled for completion by July 29, 2025. As a non-set-aside, competitively awarded delivery order, this award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 ml auto-injector units, valued at $2,353.38. This was a competitively awarded, firm fixed-price delivery order with an ultimate completion date of August 5, 2025. The contract contains no set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5JFDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injectors on August 5, 2025, with completion expected by August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The parent IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to deliver specialty medications, brand-name and generic drugs, vaccines, and medical devices to customers including the Defense Health Agency and U.S. Coast Guard. This specific delivery order for testosterone auto-injectors supports the DLA's medical supply chain mission and reflects the company's established capability to meet federal procurement requirements for specialized pharmaceutical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 8/5/25 |